Bariatric Surgery and Cancer Risk

How could bariatric surgery lower cancer risk?

Obesity is an established risk factor for several cancers, including postmenopausal breast, endometrial, colorectal, kidney, liver, pancreatic and esophageal adenocarcinoma. The International Agency for Research on Cancer has identified excess body fatness as causally linked to 13 cancer types, making sustained weight reduction a major area of prevention research.

Bariatric surgery produces larger and more durable weight loss than most non-surgical interventions for severe obesity, but the cancer signal is not simply a story of body mass index. Weight loss can lower insulin resistance, alter sex hormone exposure, reduce chronic inflammation and change adipokines, all of which may influence tumor initiation or progression over many years.

Why do insulin levels and sex matter in cancer prevention?

The updated PLOS Medicine analysis of the Swedish Obese Subjects study found that surgery-induced weight loss was associated with a lower hazard of incident cancer among women after long follow-up, while the same clear association was not observed in men. The study was not designed as a randomized cancer-prevention trial, so the findings should be interpreted as strong observational evidence rather than proof that surgery prevents cancer in every patient.

Insulin is biologically plausible as a modifier because high insulin and insulin-like growth signaling can promote cell growth and interact with pathways involved in breast and endometrial cancer biology. The sex difference also fits with the fact that several obesity-related cancers are hormone-sensitive, although researchers emphasize that many mechanisms likely overlap, including inflammation, estrogen metabolism and changes in adipose tissue function.

Could FTO genetics help identify who benefits most?

A Scientific Reports analysis focused on the FTO rs9939609 variant, a well-known obesity-associated genetic marker, in women from the Swedish Obese Subjects study. The findings suggest that genotype may modify the association between bariatric surgery and breast cancer incidence, especially among women with higher insulin levels at baseline.

This does not mean patients should seek FTO testing before considering bariatric surgery. Current decisions still depend on obesity severity, type 2 diabetes, cardiovascular risk, sleep apnea, surgical risk, patient goals and long-term follow-up capacity. The genetic findings are best viewed as a step toward precision prevention research rather than a clinical screening rule.